Answers are grounded in this paper and cite their sources.
IgA nephropathy (IgAN) represents the most prevalent form of glomerulonephritis, particularly in developed nations. Despite the high prevalence of this condition, treatment options remain a topic of debate. Recent years have witnessed the emergence of numerous clinical trials proposing specific treatments. In Bulgaria, patients still have limited access to novel treatments, prompting us to share our experiences with existing therapeutic modalities and advocate for enhanced knowledge and treatment evolution.
No takes yet. Share an insight, caveat, or question.
Kostadinova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: